Announcements Trials
Browse Landscape

Phase

Phase 2 60Phase 1 30Phase 1/2 14Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 2Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Endocrine 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × trametinib × Clear all
NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT01467310 2020-09-02

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡